selected scholarly activity
-
academic article
- Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Journal of the Canadian Urological Association. 15:1-15. 2020
- In Reply. Oncologist. 25. 2020
- Management of germ cell tumors during the outbreak of the novel coronavirus disease‐19 pandemic: a survey of international expertise centers. Oncologist. 2020
- Evolution of Cancer Care in Response to the COVID ‐19 Pandemic. Oncologist. 25. 2020
- A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. Journal of the Canadian Urological Association. 14:163-168. 2020
- A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 ( COVID ‐19) Pandemic: An International Collaborative Group. Oncologist. 25:e936-e945. 2020
- In Reply. Oncologist. 25:E1252-E1253. 2020
- A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer. 143:1-11. 2020
- Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology. 2020
- Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Journal of the Canadian Urological Association. 14:E154-E158. 2020
- A A Canadian consensus forum on the management of patients with advanced prostate cancer. Journal of the Canadian Urological Association. 14:E137-E149. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:122-129. 2020
- Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clinical Cancer Research. 26:1114-1125. 2020
- Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. Journal of the Canadian Urological Association. 14:E57-E64. 2020
- Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology. 22:437-437. 2020
- Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Journal of the Canadian Urological Association. 13:343-54. 2019
- OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. Current Oncology. 26:e618-e623. 2019
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clinical Genitourinary Cancer. 17:201-208.e1. 2019
- Reversible Cabozantinib-Induced Cardiomyopathy. Canadian Journal of Cardiology. 35:544.e1-544.e2. 2019
- Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. Targeted Oncology. 14:43-55. 2019
- Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Targeted Oncology. 14:67-74. 2019
- The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer. 108:69-77. 2019
- Enhancing diversity or upping uncertainty?. Journal of the Canadian Urological Association. 13:396-403. 2019
- Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report. Journal of Medical Case Reports. 12:373. 2018
- Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Journal of the Canadian Urological Association. 12:328-336. 2018
- Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Journal of the Canadian Urological Association. 12:173-80. 2018
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 36:1521-1539. 2018
- A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Investigational New Drugs. 36:278-287. 2018
- A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget. 9:8155-8164. 2018
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. The Lancet Oncology. 18:1532-1542. 2017
- Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Journal of the Canadian Urological Association. 11:310-320. 2017
- Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer. Annals of Internal Medicine. 167:341-341. 2017
- Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care — Cancer Care Ontario Clinical Practice Guideline. Clinical Oncology Comparative Haematology International. 29:348-355. 2017
- First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Journal of the Canadian Urological Association. 11:112-112. 2017
- Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins. Future Oncology. 13:369-379. 2017
- Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). European Journal of Cancer. 72:192-199. 2017
- Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 27:vi269-vi269. 2016
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer immunology research. 4:881-892. 2016
- A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Annals of Oncology. 27:1116-1122. 2016
- A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. 34:104-111. 2016
- Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer. Heliyon. 2:e00059-e00059. 2016
- Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Annals of Oncology. 26:2044-2056. 2015
- The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). Journal of the Canadian Urological Association. 9:90-90. 2015
- Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. The Lancet Oncology. 16:208-220. 2015
- Long-term Survival in a Patient with Metastatic Spinal Cord Compression from a Prostate Cancer with Ultra-high PSA: Case Report and Review of the Literature. Cureus. 7:e242. 2015
- A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. British Journal of Cancer. 111:2262-2267. 2014
- A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 32:1226-1235. 2014
- Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. Journal of the Canadian Urological Association. 8:398-398. 2014
- Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology. 32:3436-3448. 2014
- A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investigational New Drugs. 32:1005-1016. 2014
- Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet Oncology. 15:1263-1268. 2014
- Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations Seminars in Urologic Oncology. 32:975-980. 2014
- A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. Canadian Urological Association Journal. 8:583-583. 2014
- A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. Investigational New Drugs. 32:746-752. 2014
- Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. Clinical Biochemistry. 47:897-900. 2014
- Phase II trial of vorinostat in advanced melanoma. Investigational New Drugs. 32:526-534. 2014
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs. 32:243-249. 2014
- Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. European Journal of Human Genetics. 22:391-395. 2014
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational New Drugs. 31:1182-1191. 2013
- CUAJ Correction October 2013. Journal of the Canadian Urological Association. 7:301-301. 2013
- A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). British Journal of Cancer. 109:943-949. 2013
- A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Investigational New Drugs. 31:1008-1015. 2013
- Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Medicine. 2:468-477. 2013
- CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. Journal of the Canadian Urological Association. 7:231-231. 2013
- Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Clinical Oncology Comparative Haematology International. 25:406-430. 2013
- Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. International Journal of Cancer. 132:1547-1555. 2013
- A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Annals of Oncology. 24:761-769. 2013
- Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 71:543-549. 2013
- A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Investigational New Drugs. 30:1652-1659. 2012
- A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Annals of Oncology. 23:1562-1570. 2012
- MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma. Cancer Investigation. 30:415-421. 2012
- An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer. 48:324-332. 2012
- The Quality-of-Life Impact of Head and Neck Cancer: Preference Values from the Canadian General Public. Health Outcomes Research in Medicine. 3:e11-e23. 2012
- A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology. 23:53-58. 2012
- Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC). Clinical Biochemistry. 44:1273-1277. 2011
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs. 29:1045-1049. 2011
- Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.. Current Oncology. 18 Suppl 2:S11-S19. 2011
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research. 17:5765-5773. 2011
- Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy—systematic review and recommendations for clinical practice. Current Oncology. 18:e191-e201. 2011
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 67:927-933. 2011
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17:1582-1590. 2011
- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 104:756-762. 2011
- A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology. 33:609-613. 2010
- Guidelines for the management of castrate-resistant prostate cancer. Journal of the Canadian Urological Association. 4:380-384. 2010
- Case Report: Celiac Disease Masquerading As Bone Metastasis in a 29-Year-Old Woman. Journal of Clinical Oncology. 28:e623-e625. 2010
- Current management of castrate-resistant prostate cancer. Current Oncology. 17:S72-S79. 2010
- The unclear zone in phase II clinical trials. European Journal of Cancer. 46:2408-2413. 2010
- Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Canadian Urological Association Journal. 4:201-201. 2010
- Canadian consensus guidelines for the management of testicular germ cell cancer. Journal of the Canadian Urological Association. 4:19-19. 2010
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 116:1272-1280. 2010
- Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?. Clinical Cancer Research. 16:1341-1341. 2010
- Management of Stage I Non-seminomatous Testicular Cancer: a Systematic Review and Meta-analysis. Clinical Oncology Comparative Haematology International. 22:17-26. 2010
- Current management of castrate-resistant prostate cancer. Current Oncology. 17. 2010
- Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology. 78:340-347. 2010
- Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head and Neck Surgery Head and Neck. 31:1006-1012. 2009
- Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update (vol 3, pg 200, 2009). Journal of the Canadian Urological Association. 3:289-289. 2009
- Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent. Clinical Biochemistry. 42:1162-1165. 2009
- Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.. Clinical Cancer Research. 27. 2009
- Role of cytokine therapy for Renal Cell Carcinoma in the era of targeted agents. Current Oncology. 16:S40-S44. 2009
- Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opinion on Investigational Drugs. 18:311-325. 2009
- Treatment of adult rhabdoid renal cell carcinoma with sorafenib. Journal of the Canadian Urological Association. 2:631-631. 2008
- Understanding the Results of Meta-Analyses in the Treatment of Head and Neck Squamous Cell Cancer. Hematology/Oncology Clinics of North America. 22:1257-1266. 2008
- Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones. Journal of Clinical Oncology. 26:3301-3302. 2008
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14:3450-3455. 2008
- Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement.. Journal of the Canadian Urological Association. 2:175-182. 2008
- A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology. 19:746-751. 2008
- Cardiotoxicity associated with sunitinib. The Lancet. 371:1244-1244. 2008
- A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research. 14:833-839. 2008
- Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochimica et Biophysica Acta - Molecular Basis of Disease. 1772:1134-1142. 2007
- Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. Journal of Clinical Oncology. 25:3978-3984. 2007
- Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13:4849-4857. 2007
- Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Investigational New Drugs. 25:471-477. 2007
- UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. Gynecologic Oncology. 106:305-310. 2007
- Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Canadian Urological Association Journal. 1:S28-S33. 2007
- Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 1. 2007
- Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: Moving to guidelines. Journal of the Canadian Urological Association. 1. 2007
- Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines. Canadian Urological Association Journal. 1:S34-S40. 2007
- Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Canadian Urological Association Journal. 1:27-38. 2007
- An Optimized Clinical Regimen for the Oncolytic Virus PV701. Clinical Cancer Research. 13:977-985. 2007
- Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer. 6:112. 2006
- Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of Oncology. 17:334-340. 2006
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Annals of Oncology. 16:1688-1694. 2005
- In Reply:. Journal of Clinical Oncology. 23:6273-6274. 2005
- Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study. Journal of Clinical Oncology. 23:585-590. 2005
- High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre.. Sarcoma. 8:63-69. 2004
- Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.. Current Opinion in Molecular Therapeutics. 5:618-624. 2003
- BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies. Current Pharmaceutical Design. 8:2249-2253. 2002
- Plasma osteopontin. Cancer. 95:506-512. 2002
- Zoledronic acid: An overview of its current and potential benefits in patients with malignancy. Today's Therapeutic Trends. 20:197-219. 2002
- Hypercalcemia of Malignancy. American Journal of Cancer. 1:179-187. 2002
-
conference paper
- A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs. 1442-1447. 2020
- A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. viii271-viii272. 2018
- Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data. Annals of Oncology. 2017
- Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.. Journal of Clinical Oncology. TPS5095-TPS5095. 2017
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. e16078-e16078. 2017
- Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.. Journal of Clinical Oncology. e14637-e14637. 2017
- Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. Journal of Clinical Oncology. 4514-4514. 2017
- Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial. Annals of Oncology. vi335-vi335. 2016
- Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 2016
- Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology. vi285-vi285. 2016
- genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. vi564-vi564. 2016
- Androgen receptor axis-targeted agents. Canadian Urological Association Journal. 146-146. 2016
- Chemotherapy research for metastatic prostate cancer. Canadian Urological Association Journal. 140-140. 2016
- Localized prostate cancer. Canadian Urological Association Journal. 138-138. 2016
- Radionulcides. Canadian Urological Association Journal. 144-144. 2016
- Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology. 4532-4532. 2016
- Abstract 4346: Prognostic gene signature for intermediate risk prostate cancer. Cancer Research. 2015
- A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 2541-2541. 2015
- Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 4555-4555. 2015
- Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248).. Journal of Clinical Oncology. 6053-6053. 2015
- IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.. Journal of Clinical Oncology. 279-279. 2015
- The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.. Journal of Clinical Oncology. 424-424. 2015
- 508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041). European Journal of Cancer. 165-166. 2014
- Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.. Journal of Clinical Oncology. 5061-5061. 2014
- Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.. Journal of Clinical Oncology. 6041-6041. 2014
- Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.. Journal of Clinical Oncology. 222-222. 2014
- Phosphaturic Mesenchymal Tumour (PMT) of the Ethmoid Sinus, Confirmed with Chromogenic In-Situ Hybridization for FGF23. Journal of Bone and Mineral Research. S486-S487. 2014
- A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. Journal of Clinical Oncology. 2013
- A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.. Journal of Clinical Oncology. 2013
- A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.. Journal of Clinical Oncology. 2013
- A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 2013
- Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 2013
- Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial. Journal of Clinical Oncology. 2013
- Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy. Journal of Clinical Oncology. 2013
- NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 2013
- Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr plus T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041). Journal of Clinical Oncology. 2013
- Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program. Journal of Clinical Oncology. 2013
- 1440 EMERGENCE OF VARIANT HISTOLOGY DURING NEO-ADJUVANT CHEMO-THERAPY FOR MUSCLE INVASIVE URETHELIAL BLADDER CANCER IS COMMON AND ASSOCIATED WITH POOR PROGNOSIS. JOURNAL OF UROLOGY. E590-E590. 2013
- 1441 INCIDENCE, CHARACTERISTICS, AND IMPLICATIONS OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER UNDERGOING CISPLATIN BASED NEO-ADJUVANT CHEMOTHERAPY. JOURNAL OF UROLOGY. E590-E591. 2013
- A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 113-113. 2013
- Utilization of Radiation Therapy in Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice. International Journal of Radiation Oncology Biology Physics. S361-S362. 2012
- A PHASE I STUDY OF THE COMBINATION OF RO4929097 (RO) AND CEDIRANIB (CD) IN PATIENTS WITH ADVANCED SOLID TUMORS (PJC-004/NCI 8503). Annals of Oncology. 155-156. 2012
- A PHASE IB COMBINATION STUDY OF RO4929097 (RO), A GAMMA-SECRETASE INHIBITOR, AND TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. Annals of Oncology. 156-156. 2012
- A RANDOMIZED PHASE II STUDY OF OGX-427 PLUS PREDNISONE (P) VS. P ALONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC). Annals of Oncology. 297-297. 2012
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Journal of Clinical Oncology. 2012
- A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN).. Journal of Clinical Oncology. 2012
- A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). Journal of Clinical Oncology. 2012
- Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.. Journal of Clinical Oncology. 2012
- A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients. Cancer Research. 2012
- A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 121-121. 2012
- NT-proBNP measurement using a multiplex platform in cancer and chest pain populations. Clinical Biochemistry. 1172-1172. 2011
- Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. e15153-e15153. 2011
- Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 5561-5561. 2011
- Neoadjuvant temsirolimus in high-risk renal cell carcinoma: Results from a single-center prospective study.. Journal of Clinical Oncology. 387-387. 2011
- 491 NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly. European Journal of Cancer, Supplement. 157-157. 2010
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 4247-4254. 2010
- Early changes in biomarkers determined by LC/MS/MS and ELISA based methods in a phase I/II study assessing an anti-metastatic agent. Clinical Biochemistry. 781-782. 2010
- Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.. Journal of Clinical Oncology. 3077-3077. 2010
- Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 2010
- Preventing patupilone-induced diarrhea with high-dose corticosteroids.. Journal of Clinical Oncology. e13069-e13069. 2010
- Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies. Cancer Research. 2010
- Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. Molecular Cancer Therapeutics. 2009
- Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB‐family inhibitor ARRY‐334543 in patients with advanced solid tumors. Molecular Cancer Therapeutics. 2009
- P71 Vascular endothelial growth factor (VEGF) inhibition and erythropoiesis – a missing link?. European Journal of Cancer, Supplement. 36-36. 2009
- 7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC). European Journal of Cancer, Supplement. 407-407. 2009
- 7014 A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive Castrate Resistant Prostate Cancer (CRPC). European Journal of Cancer, Supplement. 410-410. 2009
- 7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC). European Journal of Cancer, Supplement. 413-414. 2009
- A mass spectrometry approach to identify surrogate biomarkers; for early responders to an anti-metastatic/anti-tumor investigational agent. Clinical Chemistry. A114-A115. 2009
- Cytokines and cell adhesion molecules exhibit cancer specific profiles in patients with metastatic disease treated with an investigational anti-metastatic agent. Clinical Chemistry. A116-A117. 2009
- A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. Journal of Clinical Oncology. 2009
- Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada. Journal of Clinical Oncology. 2009
- Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer. Journal of Clinical Oncology. 2009
- Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 2009
- OGX-427, a 2 ' methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. Journal of Clinical Oncology. 2009
- Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL). Journal of Clinical Oncology. 2009
- Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 2009
- A phase I study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms: final report. Cancer Research. 2009
- PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA. Value in Health. A49-A49. 2009
- CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY. JOURNAL OF UROLOGY. 229-230. 2009
- 112 POSTER A clinical chemistry approach for identifying biomarkers as surrogate endpoints in therapy directed against chemokine mediated metastasis. European Journal of Cancer, Supplement. 37-37. 2008
- 206 POSTER Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC). European Journal of Cancer, Supplement. 65-65. 2008
- 405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. European Journal of Cancer, Supplement. 127-127. 2008
- A PHASE 2 STUDY OF PATUPILONE IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (HRPC) WHO HAVE PROGRESSED AFTER DOCETAXEL. Annals of Oncology. 189-189. 2008
- Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 257-264. 2008
- A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. Journal of Clinical Oncology. 5002-5002. 2008
- A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. Journal of Clinical Oncology. 2008
- Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. Journal of Clinical Oncology. 2008
- Correlation of computerized tomography measurement of visceral adiposity with plasma adiponectin levels and presence of metastatic disease in patients with clear cell renal cell carcinoma. Journal of Clinical Oncology. 5118-5118. 2008
- Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear cell carcinoma of the kidney. Journal of Clinical Oncology. 22225-22225. 2008
- Progression free survival in patients with metastatic and recurrent renal cancer treated with sorafenib—Single center experience. Journal of Clinical Oncology. 16141-16141. 2008
- The unclear zone in phase II clinical trials. Journal of Clinical Oncology. 6519-6519. 2008
- Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications. Journal of Clinical Oncology. 2205-2211. 2008
- SORAFENIB THERAPY IN THE MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA WITH BRAIN METASTASES: RESULTS FROM THE ARCCS EXPANDED ACCESS PROGRAM. European Urology, Supplements. 245-245. 2008
- A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. Molecular Cancer Therapeutics. 3371S-3371S. 2007
- AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium. Molecular Cancer Therapeutics. 3337S-3338S. 2007
- Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Molecular Cancer Therapeutics. 3385S-3386S. 2007
- Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Journal of the Canadian Urological Association. S28-S33. 2007
- Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines. Journal of the Canadian Urological Association. S34-S40. 2007
- 550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors. European Journal of Cancer, Supplement. 167-167. 2006
- A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT).. Journal of Clinical Oncology. 296S-296S. 2006
- A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Annals of Oncology. 179-179. 2006
- A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC). Annals of Oncology. 186-186. 2006
- Phase II study of bay 43-9006 (SORAFENIB) in patients with chemo-naive hormone refractory prostate cancer (HRPC). Annals of Oncology. 152-152. 2006
- A phase 2 study of GTI-2040 plus docetaxel and prednisone as 1st line treatment in hormone-refractory prostate cancer (HRPC).. Clinical Cancer Research. 8974S-8974S. 2005
- HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.. Clinical Cancer Research. 9104S-9104S. 2005
- A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154.. Journal of Clinical Oncology. 213S-213S. 2005
- HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.. Journal of Clinical Oncology. 204S-204S. 2005
- Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 171S-171S. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 204S-204S. 2004
- Phase II study of topotecan (T) in combination with the novel kinase inhibitor ucUCN-01 in patients with advanced cancer.. Clinical Cancer Research. 6223S-6223S. 2003
- Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours. European Journal of Cancer. S55-S55. 2002